Taysha Gene Therapies
TSHA
59 hedge funds and large institutions have $54.7M invested in Taysha Gene Therapies in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 24 reducing their positions, and 24 closing their positions.
7.97% less ownership
Funds ownership: 44.23% → 36.26% (-8%)
17% less funds holding
Funds holding: 71 → 59 (-12)
38% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 24
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
51% less capital invested
Capital invested by funds: $111M → $54.7M (-$56.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$1.76M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.23M |
| 3 |
Renaissance Technologies
New York
|
+$1.08M |
| 4 |
Millennium Management
New York
|
+$858K |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
+$655K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.55M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
-$4.34M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$1.94M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.67M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$680K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
76
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$11K | -1,745 | Closed |
|
77
Ensign Peak Advisors
Salt Lake City,
Utah
| – | -$9K | -1,410 | Closed |
|
78
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$6 | -867 | Closed |
|
79
Simplex Trading
Chicago,
Illinois
| – | -$1.27K | -320 | Closed |
|
80
Osaic Holdings
Scottsdale,
Arizona
| – | -$2K | -241 | Closed |
|
|
TFO
81
Tarbox Family Office
Newport Beach,
California
| – | -$1K | -175 | Closed |
|
|
S
82
SignatureFD
Atlanta,
Georgia
| – | -$1K | -165 | Closed |
|
TSHA Hedge Fund Activity: Q2 2022 in Review
59 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q2 2022, worth a combined $54.7M — down 51% from $111M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of TSHA and 14 opened new positions — a net loss of 10 holders — while 24 trimmed existing stakes and 15 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $1.76M. The largest seller was BlackRock, cutting an estimated $4.55M.
- 59 institutional investors held Taysha Gene Therapies (TSHA) as of Q2 2022, down from 71 in Q1 2022.
- Funds reported $54.7M of Taysha Gene Therapies stock for Q2 2022, down 51% quarter-over-quarter.
- 14 funds opened new Taysha Gene Therapies positions in Q2 2022 and 24 closed out, a net change of -10 holders.
- The largest Taysha Gene Therapies buyer in Q2 2022 was Laurion Capital Management, an estimated $1.76M added.
- The largest Taysha Gene Therapies seller in Q2 2022 was BlackRock, an estimated $4.55M sold.
Based on aggregated 13F filings for Q2 2022.